BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27465286)

  • 1. Candidate microRNAs as biomarkers of thyroid carcinoma: a systematic review, meta-analysis, and experimental validation.
    Hu Y; Wang H; Chen E; Xu Z; Chen B; Lu G
    Cancer Med; 2016 Sep; 5(9):2602-14. PubMed ID: 27465286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review.
    Chruścik A; Lam AK
    Exp Mol Pathol; 2015 Dec; 99(3):393-8. PubMed ID: 26321247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-based molecular classification of papillary thyroid carcinoma.
    Rosignolo F; Memeo L; Monzani F; Colarossi C; Pecce V; Verrienti A; Durante C; Grani G; Lamartina L; Forte S; Martinetti D; Giuffrida D; Russo D; Basolo F; Filetti S; Sponziello M
    Int J Oncol; 2017 May; 50(5):1767-1777. PubMed ID: 28393181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA signature predicts survival in papillary thyroid carcinoma.
    Chengfeng X; Gengming C; Junjia Z; Yunxia L
    J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma.
    Liu X; He M; Hou Y; Liang B; Zhao L; Ma S; Yu Y; Liu X
    Oncol Rep; 2013 Apr; 29(4):1415-20. PubMed ID: 23380809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
    Qiu Z; Li H; Wang J; Sun C
    Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
    Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
    Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting.
    Napoli F; Rapa I; Mortara U; Massa F; Izzo S; Rigutto A; Zambelli V; Bellevicine C; Troncone G; Papotti M; Volante M
    Cancer Cytopathol; 2022 Sep; 130(9):695-704. PubMed ID: 35500065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Landscape of Circular RNA Expression Profiles in Papillary Thyroid Carcinoma Based on RNA Sequencing.
    Lan X; Xu J; Chen C; Zheng C; Wang J; Cao J; Zhu X; Ge M
    Cell Physiol Biochem; 2018; 47(3):1122-1132. PubMed ID: 29847813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
    Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
    Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
    Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
    Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma.
    Min XS; Huang P; Liu X; Dong C; Jiang XL; Yuan ZT; Mao LF; Chang S
    Tumour Biol; 2015 Sep; 36(10):7457-63. PubMed ID: 25908172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
    Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
    Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family.
    Perdas E; Stawski R; Nowak D; Zubrzycka M
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma.
    Rossing M; Borup R; Henao R; Winther O; Vikesaa J; Niazi O; Godballe C; Krogdahl A; Glud M; Hjort-Sørensen C; Kiss K; Bennedbæk FN; Nielsen FC
    J Mol Endocrinol; 2012 Feb; 48(1):11-23. PubMed ID: 22049245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of key genes and miRNAs markers of papillary thyroid cancer.
    Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
    Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
    Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
    Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.